These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30794024)

  • 1. Definitive urine drug testing in office-based opioid treatment: a literature review.
    Barthwell AG; Allgaier J; Egli K
    Crit Rev Toxicol; 2018 Nov; 48(10):829-852. PubMed ID: 30794024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine.
    Guo AY; Ma JD; Best BM; Atayee RS
    J Anal Toxicol; 2013; 37(9):636-41. PubMed ID: 24080973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS.
    West R; Mikel C; Hofilena D; Guevara M
    Drug Alcohol Depend; 2018 Dec; 193():183-191. PubMed ID: 30391868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder.
    Holt SR; Donroe JH; Cavallo DA; Tetrault JM
    Drug Alcohol Depend; 2018 May; 186():171-174. PubMed ID: 29579725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment.
    Suzuki J; Zinser J; Issa M; Rodriguez C
    Subst Abus; 2017; 38(4):504-507. PubMed ID: 28723256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
    Heikman P; Sundström M; Pelander A; Ojanperä I
    Hum Psychopharmacol; 2016 Jan; 31(1):44-52. PubMed ID: 26763789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses.
    Bi-Mohammed Z; Wright NM; Hearty P; King N; Gavin H
    Drug Alcohol Depend; 2017 Feb; 171():122-131. PubMed ID: 28086177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests.
    Bagley SM; Cheng DM; Winter M; Alford DP; LaBelle C; Walley AY; Samet JH
    Drug Alcohol Depend; 2018 Nov; 192():245-249. PubMed ID: 30290291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.
    ESUB-MG Study Group
    BMC Fam Pract; 2016 Mar; 17():24. PubMed ID: 26931763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
    Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
    J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Patients' Direct Addition of Buprenorphine to Urine Drug Test Specimens With Clinical Factors in Opioid Use Disorder.
    Pytell JD; Whitley P; Passik SD; Bundy WL; Dawson E; Saloner B
    JAMA Psychiatry; 2023 May; 80(5):459-467. PubMed ID: 36947029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent subjects.
    Balhara YP; Jain R
    J Opioid Manag; 2012; 8(1):45-9. PubMed ID: 22479884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine Treatment for Opioid Use Disorder in Community-Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results.
    Galanter M; Femino J; Hunter B; Hauser M
    Am J Addict; 2020 Jul; 29(4):271-278. PubMed ID: 32162434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
    Accurso AJ; Lee JD; McNeely J
    J Subst Abuse Treat; 2017 Dec; 83():62-67. PubMed ID: 29129197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observations on the effects of buprenorphine and methadone on illicit drug use.
    Pesce AJ; Tran K; Krock K; Cua A; Thomas R
    J Opioid Manag; 2024; 20(3):193-195. PubMed ID: 39017611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations.
    Argoff CE; Alford DP; Fudin J; Adler JA; Bair MJ; Dart RC; Gandolfi R; McCarberg BH; Stanos SP; Gudin JA; Polomano RC; Webster LR
    Pain Med; 2018 Jan; 19(1):97-117. PubMed ID: 29206984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.